Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06644768 · ClinicalTrials.gov registry record · Phase 1

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 1
Development phase
137
Enrollment target
20
Study locations

NCT06644768 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 137 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06644768, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 1
Development phase
137 participants
Enrollment target
20
Study locations

Study Summary

This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations

Conditions Studied

Non-Small Cell Lung Cancer Lung Cancer

Interventions

  • DRUG pembrolizumab
  • DRUG valemetostat tosylate

Study Locations (20)

Other

  • Hospital Italiano de Buenos Aires - Buenos Aires
  • Instituto Alexander Fleming - Buenos Aires
  • Sanatorio Allende - Córdoba
  • Fundacion Ars Medica - N Salvador de Jujuy
  • Centro de Investigacion Pergamino Sa - Pergamino
  • Instituto Medico de La Fundacion Estudios Clinicos - Rosario
  • Clinica Viedma S.A. - Viedma
  • Centro de Pesquisas Clinica Reichow - Blumenau

California

  • University of California San Diego (Ucsd)-Moores Cancer Center - La Jolla
  • California Research Institute - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles

Florida

  • Mayo Clinic Hospital - Jacksonville
  • BRCR Global - Plantation

Kentucky

  • University of Kentucky Medical Center - Lexington
  • Pikeville Medical Center - Pikeville

New York

  • Columbia University Irving Medical Center - New York
  • Montefiore Medical Center - The Bronx

Minnesota

  • Mayo Clinic - Rochester - Rochester

Pennsylvania

  • Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia

Virginia

  • Virginia Cancer Specialist - Fairfax

Trial Details

FieldValue
Enrollment Target 137 participants
Start Date 2024-10-30
Est. Completion 2030-04-30
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06644768

The ClinicalTrials.gov registry entry for NCT06644768 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.

NCT06644768 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06644768 about?

NCT06644768 is a clinical study titled "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations". This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations

What is the current status of trial NCT06644768?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2024-10-30. Estimated completion is 2030-04-30.

What conditions does trial NCT06644768 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer.

What interventions are being tested in trial NCT06644768?

The interventions under investigation include: pembrolizumab (DRUG), valemetostat tosylate (DRUG).

Who is sponsoring clinical trial NCT06644768?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06644768 being conducted?

This trial has 20 study locations across California, Florida, Kentucky, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.